Navigation Links
Shanghai ChemPartner and Agios Expand Integrated Drug Discovery Research Collaboration
Date:7/9/2009

SHANGHAI, July 9 /PRNewswire-Asia/ -- Shanghai ChemPartner Co., Ltd., (ChemPartner) a wholly owned subsidiary of ShangPharma Corporation, today announces that it has expanded its integrated drug discovery research collaboration with Agios, the first biopharmaceutical company dedicated to the development of novel therapeutics in the emerging field of cancer metabolism. ChemPartner will provide integrated services in the areas of protein science, HTS, in vitro enzyme assay, cell biology, in vivo pharmacology, etc., for Agios' innovative R&D program to discover novel clinical candidates for oncology indications.

Michael Hui, founder and CEO of ChemPartner, said, "ChemPartner is pleased to build upon this existing collaboration and work closely with the experienced scientists at Agios to develop new clinical compounds for oncology indications. The partnership demonstrates the strength and breadth of our integrated drug discovery and development capabilities and this is a wonderful opportunity to share expertise and complement strengths."

"Due to the rapid success and progression of our pipeline and platform, Agios has experienced a need for significant resource assistance. ChemPartners has been able to help us address these needs quickly with high quality and quick responsiveness," said Michael Su, Vice President of Drug Discovery, Agios Pharmaceuticals. "ChemPartners' flexibility, scientific expertise, problem-solving skills as well as its comprehensive and integrated service platform have made them an invaluable partner in our continuing leadership strategy of the exciting, breakthrough field of cancer metabolism."

About Shanghai ChemPartner

Founded in 2003, Shanghai ChemPartner Company Ltd. (ChemPartner) is one of the leading contract research organizations providing medicinal chemistry, discovery biology, pharmacology, DMPK, toxicology, process R&D, analytical development, formulation and contract manufacturing services to over 80 pharmaceutical and biotech companies in the world. ChemPartner currently has a team of over 1,000 scientists including over 80 senior scientific leaders with extensive industry experiences gained from leading global pharmaceutical and biotech companies.

Further information is available at http://www.shangpharma.com .


'/>"/>
SOURCE Shanghai ChemPartner Co., Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Shanghai Century Acquisition Corporation Announces Sichuan Kelun Pharmaceutical Co Results for the Six Months Ended June 30, 2007
2. HUYA Bioscience International Licenses Clinical Stage Anti-Arrhythmic Compound from the Shanghai Institute of Materia Medica
3. Cinpathogen Brings Together Over 40 Shanghai Area Hospitals at the First Annual Cinpathogen Hematology Conference
4. Cinpathogen Provides Clinical Diagnostic Consulting Services to Shanghai Area Hospitals
5. Shanghai CRO Service Alliance Adds Clinical Development Capabilities
6. Carna Biosciences Signs Distribution Agreement with Shanghai Universal Biotech Company
7. Cynvec to Present at the 11th Annual Shanghai International Forum on Biotechnology and Pharmaceutical Industry
8. NeoStem Signs Agreement with Shanghai Corporation to Develop A Stem Cell Collection and Treatment Network in Shanghai, Taiwan and Other Targeted China Provinces
9. Sundia and 2 Other CRO Companies Granted Express Customs Clearance Privilege in Shanghai
10. Phlo Affiliate Reports Expanded Coverage to Oregon Border
11. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... 2016  SRI International has been awarded a ... National Institutes of Health,s National Institute of Allergy ... (NIAID-DAIDS) to support the manufacturing and characterization of ... Under the seven-year contract, SRI will provide a ... candidate HIV-prevention products that emerge from investigator-initiated studies ...
(Date:12/6/2016)... ... December 06, 2016 , ... RoviSys, a leading ... in Aurora, Ohio, announced the opening of their new office building today. Located ... facility is home to 200 employees focused on providing sales, engineering, and support ...
(Date:12/5/2016)... Dec 5, 2016 Research and Markets ... - Technologies, Markets and Companies" to their offering. ... , , ... discovery using various -omics technologies such as proteomics and metabolomics. Molecular ... tests are also based on biomarker. Currently the most ...
(Date:12/5/2016)... , December 5, 2016 ... "Cell Expansion Market, by Products (Consumable, Instruments, Automated ... (Regenerative Medicine and Stem Cell Research, Cancer, and ... Institutes, Cell Banks) - Global Revenue, Trends, Growth, ... Scalar Market Research, the global cell expansion market ...
Breaking Biology Technology:
(Date:12/6/2016)... Biomet Holdings, Inc. (NYSE and SIX: ZBH) (the "Company") today ... principal amount of its 1.414% senior unsecured notes due 2022 ... notes due 2026. The closing of the ... the satisfaction of customary closing conditions.  The notes will pay ... The Company intends to use the net proceeds from the ...
(Date:12/6/2016)... -- Valencell , the leading innovator in performance ... third consecutive year of triple digit growth for its ... a 360 percent increase in companies who have acquired ... by sales of its wrist and ear Benchmark™ sensor ... for hearables for fitness and healthcare applications. ...
(Date:12/6/2016)... Dec. 6, 2016 Securus Technologies, a ... solutions for public safety, investigation, corrections and monitoring, ... today a five (5) year funding commitment by ... expand the rehabilitation and reentry support to more ... Established in 2004, the Prison Entrepreneurship Program (PEP) ...
Breaking Biology News(10 mins):